Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Cipher Pharmaceuticals Inc    CPH   CA17253X1050

CIPHER PHARMACEUTICALS INC (CPH)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
3.09(c) 3.04(c) 3.05(c) 3.15(c) 3.05(c) Last
34 518 22 750 9 200 20 973 21 505 Volume
-1.90% -1.62% +0.33% +3.28% -3.17% Change
More quotes
Financials (USD)
Sales 2018 26,2 M
EBIT 2018 8,76 M
Net income 2018 16,3 M
Finance 2018 19,1 M
Yield 2018 -
Sales 2019 32,5 M
EBIT 2019 11,0 M
Net income 2019 -
Finance 2019 36,9 M
Yield 2019 -
P/E ratio 2018 10,16
P/E ratio 2019 5,74
EV / Sales2018 1,76x
EV / Sales2019 0,87x
Capitalization 65,2 M
More Financials
Company
Cipher Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the robust and diversified portfolio of commercial and late-stage products.It also acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and... 
Sector
Pharmaceuticals
Calendar
10/31Earnings Release
More about the company
Latest news on CIPHER PHARMACEUTICALS INC
09/20CIPHER PHARMACEUTICALS : Acquires Exclusive Canadian Rights to MOB-015 from Mobe..
AQ
09/18CIPHER PHARMACEUTICALS : Acquires Exclusive Canadian Rights to MOB-015 from Mobe..
AQ
09/18MOBERG PHARMA PUBL : and Cipher Pharmaceuticals sign exclusive license agreement..
AQ
09/12CIPHER PHARMACEUTICALS : Receives Health Canada Approval of Xydalba
AQ
09/10CIPHER PHARMACEUTICALS : Receives Health Canada Approval of Xydalba™ (dalb..
AQ
08/29Today's Research Reports on Neovasc, Trillium Therapeutics, Cipher Pharmaceut..
AC
08/17CIPHER PHARMACEUTICALS : Reports Q2 2018 Results
AQ
08/10CIPHER PHARMACEUTICALS : Reports Q2 2018 Results
AQ
08/02CIPHER PHARMACEUTICALS : Announces Amended Distribution and Supply Agreement for..
AQ
07/30Today's Research Reports on Cipher Pharmaceuticals, Aurinia Pharmaceuticals, ..
AC
More news
Sector news : Pharmaceuticals - NEC
09/24ASTRAZENECA : EU Grants Marketing Authorization to AstraZeneca's Imfinzi
DJ
09/24ALEXION PHARMACEUTICALS : Soliris Meets Main Endpoint in Central Nervous System ..
DJ
09/24ASTRAZENECA : Mixed Results from Farxiga Trial
DJ
09/24SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/24As China builds biotech sector, cash floods U.S. startups
RE
More sector news : Pharmaceuticals - NEC
Latest Tweets
09/18Cipher Pharmaceuticals $CHP.to Acquires Exclusive Canadian Rights to MOB-015 .. 
09/18Moberg Pharma and Cipher Pharmaceuticals sign exclusive license agreement for.. 
09/05UPSIDE MOMENTUM ALERT: $CORV CORREVIO PHARMA CORP ORDINARY SHARES ? TradeIdea.. 
09/05$CORV Correvio Pharma shares surge after preliminary test results in Europe o.. 
08/22Zacks Investment Research Lowers Correvio Pharma Q3 2018 Earnings Estimates t.. 
More tweets
Qtime:9
News from SeekingAlpha
08/10Cipher's (CPHRF) CEO Robert Tessarolo on Q2 2018 Results - Earnings Call Tran.. 
08/10Cipher Pharmaceuticals reports Q2 results 
05/31SYNERGY PHARMA : Is Management Really That Bad? 
05/11Cipher's (CPHRF) CEO Robert Tessarolo on Q1 2018 Results - Earnings Call Tran.. 
05/10Cipher Pharmaceuticals reports Q1 results 
Chart CIPHER PHARMACEUTICALS INC
Duration : Period :
Cipher Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CIPHER PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 5,06 $
Spread / Average Target 107%
EPS Revisions
Managers
NameTitle
Robert D. Tessarolo President, Chief Executive Officer & Director
Mark A. Beaudet Chairman
Stephen L. Lemieux Chief Financial Officer & Secretary
John Douglas Mull Independent Director
Christian Godin Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CIPHER PHARMACEUTICALS INC-35.71%63
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092